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TMB-8, a putative inhibitor of intra~llular calcium mobili~tion, prevents the binding of the muscarinic ligand ~-~HJme~yl~o~lamine. The 
inhibition was observed in four tissues from guinea pig; cortex, heart, pancreas, and ileum, representing MI, cardiac M2, glandular M2, and hetero- 
geneous M2 subtypes of muscarinic receptors, respectively. The KI values for all four tissues were approx. 4 /IM. However, dissociation kinetics 
revealed that TMB-8 interacted with an allosteric site of three muscarinic receptor subtypes but not the subtype from pancreas. These results indicate 
that TMB-8 interacts with muscarinic receptors, and therefore would disrupt calcium mobilization or any second messenger system coupled to 
these receptors. 
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1. INTRODUCTION 
The mode of action of 8(N,N-diethylamino)octyl- 
3,4,5-trimethoxybenzoate-HCl (TMB-8) has been attri- 
buted mainly to the inhibition of intracellular calcium 
mobilization, specifically preventing the release of 
calcium ions from the endoplasmic reticulum, but not 
Ca2+ influx [1,2]. In a number of related G-protein- 
coupled receptors, stimulation by an agonist leads to 
inositol phosphate metabolism and subsequently the 
release of Ca2+ from internal stores. TMB-8 has been 
widely used to characterize the role of Ca2+ in these 
second messenger systems ]3]. However, TMB-8 has 
diverse and apparently contradictory effects, and 
TMB-8 has even been reported to mobilize rather than 
inhibit internal Ca2+ release in pancreatic beta cells [4]. 
The effect of TMB-8 on pancreatic tissue has been 
examined because pancreatic muscarinic receptors are 
coupled to the phosphatidylinositol-Ca2+ flux second 
messenger system [S]. Phosphatidylinositol metabolism 
and Ca2+ fluxes were inhibited by TMB-8, and a shift 
of the agonist dose response curve has been observed. 
These results suggest a competitive inhibition of the 
muscarinic response in pancreatic tissue by TMB-8 
[6,7]. In addition, the binding of 13H]qui~u~lidinyl 
benzylate to the pancreas muscarinic receptor was in- 
hibited by TMB-8, although dose response and kinetic 
parameters were not reported [7]. Recently, TMB-8 has 
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been shown to inhibit muscarinic receptor-mediated 
secondary events in adrenal chromaffin cells 181, 
adrenal glands [9], and cholinergic responses in cells 
containing cloned muscarinic receptor genes [lo]. 
Whether TMB-8 competitively or allosterically in- 
teracts with muscarini~ receptor subtypes remains to be 
determined. The existence of allosteric sites on 
muscarinic subtypes is reflected by changes in the 
dissociation of a radiolabeled antagonist bound to 
these receptors [ll-131. Thus, the effect of TMB-8 on 
binding parameters was examined here in four guinea 
pig tissues representing different muscarinic receptor 
subtypes: the cortex (Ml), heart (cardiac M2), pancreas 
(glandular M2), and ileum (heterogeneous M2) 
[14-171. 
2. MATERIALS AND METHODS 
2.1. Membrane preparations 
Male guinea pigs (200-400 g) were killed by decapitation and the 
brain, heart, pancreas, and ileum removed. Each tissue was minced 
in 20-30 vofs of ice-cold buffer containing 50 mM potassium 
phosphate, pH 7.4, 8OpM EDTA, 1OOpM phenylmethylsulfonyl 
fluoride and 0.32 M sucrose, and then homogenized. Each of the 
homogenates was centrifuged at 2500 x g for 15 mitt, resuspended in 
the buffer without sucrose, and centrifuged two additional times at 
39000 X g for 20 min. 
2.2. Binding assays 
Equilibrium binding assays were performed as previously described 
[18,19]. Briefly, triplicate samples in the complete buffer were in- 
cubated with approx. 2oO~g of protein and about 1 nM of N- 
[sH]methylscopolamine ([3H]NMS; 72 Ci/mmol, New England 
Nuclear, Boston, MA), yielding total counts between 2000 and 
3000 dpm. Nonspecific binding was determined with 1 pM atropine 
and was about 100-300 dpm. TMB-8 (Sigma Chemical Co., 
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St.Louis, MO) was added with the [‘HINMS. After 45 min at 25”C, 
the assays were terminated by collecting the samples on glass-fiber 
filters with a cell harvester and washing with cold complete buffer. 
Specific binding was determined by subtracting the total from the 
nonspecific counts [18]. The IC 50 values were calculated using 
LIGAND [20]. The Ki values were derived from the ICSO values by 
correcting for receptor occupancy [21] by the [3H]NMS; the KD 
values (nM) for the four different tissues were: cortex, 0.48; heart, 
0.51; pancreas, 0.37; and ileum, 0.41. 
2.3. Dissociation kinetics assay 
The dissociation kinetics assay was performed by preincubating 
membranes containing muscarinic receptors with 1 nM [3H]NMS for 
90 min at 25°C. Subsequently, 1 pM atropine was added 
simultaneously with 0, 20, 50, or 100 FM TMB-8 for time intervals 
between 0.5 and 180 min; each assay was performed in triplicate. 
The kinetic parameters of the dissociation curves were determined 
using the equation [l I]: the [‘H]NMS bound to each tissue receptor 
(ligand-receptor complex) at a measured time (Q = .4emk-lr + 
EeVk-*? The portion of the bound ligand-receptor complex with a 
fast dissociating constant k-1 is denoted the ‘A fraction’. B is the 
fraction with a slow dissociating constant k-2. The parameters were 
fitted to curves using Gauss-Newton non-linear curve fitting pro- 
grams (ASYSTANT, Macmillan Software Co., New York, NY) in 
double-precision mode. The regression coefficients for the curves 
were between 0.98 and 1 .O. For Student’s t-tests, a P value less than 
0.05 was considered significant. 
2.4. Molecular modeling 
Molecular modeling of the protonated form of TMB-8 and 
atropine was performed as previously described [22]. Briefly, model- 
ing was accomplished using XICAMM (XIRIS Corp., New Mon- 
mouth, NJ) computer programs. These algorithms are based on the 
classical molecular mechanical approach of Wipke et al. [23], and 
result in an energy-minimized, three-dimensional model of the 
molecule. 
3. RESULTS 
Fig.1 shows the inhibition of [3H]NMS binding by 
TMB-8 in the membranes obtained from guinea pig 
cortex, heart, pancreas, and ileum, representing the 
muscarinic receptor subtypes Ml, cardiac M2, glan- 
dular M2, and heterogeneous M2, respectively. The Ki 
f SD values, determined from at least three dose- 
inhibition curves, were: cortex, 3.82 f 0.21; ileum, 
5.54 +- 0.91; pancreas, 4.24 f 0.49; heart, 5.07 f 
0.88 PM. Hence, the Ki values were all approximately 
4 PM, and were not significantly different from each 
other. The Ki values obtained from the inhibition 
curves of atropine in the cortex, heart, pancreas, and il- 
eum membranes were 1.9, 1.4, 1.1, and 2.0 nM, respec- 
tively. Therefore, based on the binding data, atropine 
was about 2000-fold more potent a muscarinic an- 
tagonist than TMB-8. Next, the effect of TMB-8 on the 
dissociation kinetics of [3H]NMS binding to the four 
different membranes was investigated. A decrease in 
the rate of dissociation of [3H]NMS from muscarinic 
receptors would indicate an allosteric interaction by 
TMB-8. 
The dissociation of bound [3H]NMS in the presence 
of atropine alone or atropine and TMB-8 are shown in 
figs 2-5 for the cortex, heart, pancreas, and ileum 
membranes, respectively. The dissociation rate con- 
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Fig. 1. Displacement by TMB-8 of [‘HJNMS bound to the muscarinic 
receptors of guinea pig membranes obtained from the cortex (0--- 
O), heart (M), pancreas (*---*), and ileum (u). Each point 
represents the mean of B 3 experiments each in triplicate, and the SD 
values were less than 9%. 
stants obtained from these figures by Gauss-Newton 
non-linear curve fitting programs are reported in table 
1. The dissociation of the [3H]NMS-receptor complex 
in the presence of atropine alone was biphasic in the 
membranes of cortex, ileum, and pancreas (table 1). In 
the heart membrane, the dissociation curve of 
[3H]NMS in the presence of atropine was monophasic, 
and thus only one dissociation constant was obtained 
(table 1). The portion of muscarinic receptors possess- 
ing a fast dissociation constant is shown in table 1 
under the heading, A fraction. A greater portion of the 
muscarinic receptor subtype in the ileum displayed a 
more rapid dissociation constant than in the cortex, 
while an even smaller portion was observed in the pan- 
creas (0.76 vs 0.51 vs 0.14, respectively, table 1). 
The dissociation curves obtained when 20-100 PM 
TMB-8 was added together with 1 PM atropine in the 
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Fig.2. Dissociation curves obtained from cortex membranes. Time 
course of the dissociation of bound [-‘H]NMS from the muscarinic 
receptors of the guinea pig membrane in the presence of the following 
drugs: 1 pM a&opine alone (*---*); 1 pM atropine and 20pM 
TMB-8 (-); 1 pM atropine and 50pM TMB-8 (O---O); and 
1 pM atropine and 100 pM TMB-8 (m- -m). Each point represents the 
mean of 23 experiments each in triplicate, and the SD values were 
less than 12%. 
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Table 1 
Dissociation constants for [3H]NMS binding to guinea pig muscarinic receptors 
Tissue Compound(s) ,uM Dissociation rate constants (mint) A fraction 
k-t k-2 
Cortex ATR 0.129 I? 0.004” 0.0176 + 0.0008” 0.51 + 0.01 
ATR + TMB-8 20 0.0405 * 0.0020 0.00640 + 0.00099 0.53 + 0.07 
ATR+TMB-8 50 0.0744 + 0.0042 0.00800 & 0.00130 0.16 + 0.01 
ATR + TMB-8 100 - 0.00337 f 0.00092 _ 
Ileum ATR 0.193 + 0.027” 0.0147 -t 0.0028 0.76 + 0.08 
ATR + TMB-8 20 - 0.0167 + 0.0043 _ 
ATR + TMB-8 50 _ 0.00529 & 0.00109 _ 
ATR + TMB-8 100 - 0.00227 + 0.00097 - 
Pancreas ATR 0.326 f 0.024 0.0151 f 0.0015 0.14 * 0.02 
ATR+TMB-8 20 0.324 f 0.029 0.0155 + 0.0021 0.15 f 0.02 
ATR+TMB-8 50 0.365 + 0.022 0.0129 + 0.0052 0.16 f 0.02 
ATR+TMB-8 100 0.308 + 0.019 0.0122 k 0.0014 0.18 + 0.02 
Heart ATR - 0.137 + 0.023” - 
ATR + TMB-8 20 _ 0.0208 + 0.0065 _ 
ATR + TMB-8 50 - 0.00383 + 0.00054 - 
ATR + TMB-8 100 - 0.000669 + 0.000094 _ 
a Significantly different compared to the corresponding dissociation constant in the pres- 
ence of TMB-8 
(- ) Monophasic kinetics rather than biphasic. After 90 min incubation with 1 nM 
[3H]NMS, 1 gM atropine (ATR) was added to each sample along with the indicated 
concentration of TMB-8, O-100 PM. The mean + SD are listed for 23 experiments, each 
in triplicate. The dissociation constants were determined as described in section 2, using 
the equation [11]: [3H]NMS bound to each tissue (ligand-receptor complex) at a measured 
time (7’) = Ae-k-lT + Be-k-2r. The portion of bound ligand-receptor complex with a fast 
dissociating constant k-1 is denoted the ‘A fraction’; B is the fraction with a slow 
dissociating constant k-2 (Le., 1 -A = B) 
pancreas membrane were similar (fig.4), and there was 
no significant difference between the dissociation rate 
constants derived from these curves (table 1). In con- 
trast to the results obtained with the pancreas mem- 
brane, higher concentrations of TMB-8 resulted in 
upward shifts of the cortex, heart, and ileum dissocia- 
tions curves, corresponding to a decrease in the 
dissociation rate constants (table 1, figs 2,3,5). 
However, the shifts in the curves were not identical for 
all muscarinic receptor subtypes. The addition of 
Fig.3. Dissociation curves obtained from heart membrane; same 
symbols and legend as fig.2. 
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20 PM TMB-8 together with 1 pM atropine significant- 
ly decreased both the k-i and k-2 dissociation con- 
stants in the cortex and ileum membranes compared to 
atropine alone (table 1, and figs 2,5). When TMB-8 was 
present at 20 PM in the ileum assay or 100 /LM in the 
cortex assay, the km1 rate constant disappeared so that 
only a single slow rate constant k-2 was observed in 
these membranes. If the fast component of dissociation 
was eliminated, TMB-8 continued to reduce the slow 
component, k-2, at higher concentrations. In the heart 
membrane, where only a monophasic kinetics constant 
was obtained with 1 PM atropine, TMB-8 decreased 
this rate constant in a dose-dependent manner (fig.3). 
4. DISCUSSION 
TMB-8 has been shown to inhibit competitively the 
pharmacological responses of pancreas slices to the 
muscarinic agonist carbachol [6,7]. These observations 
were further extended by the present study with the 
pancreas muscarinic receptor. First, TMB-8 inhibited 
[3H]NMS binding to the pancreas muscarinic receptor 
in a dose-dependent manner (fig.l), and did not alter 
either the k-1 or k-2 dissociation rate constants (fig.4, 
table 1). Hence, TMB-8 did not modulate allosterically 
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Fig.4. Dissociation curves obtained from pancreas membrane; same Fig.5. Dissociation curves obtained from ileum membrane; same 
symbols and legend as fig.2. symbols and legend as fig.2. 
[3H]NMS binding in the pancreas. These and previous 
results [22] indicate that the pancreas muscarinic recep- 
tor subtype is different from the ileum subtype. 
In contrast to the results observed with the pancreas 
tissue, TMB-8 demonstrated allosteric inhibition of the 
dissociation curves of bound [3H]NMS from 
muscarinic receptor subtypes in cortex, ileum, and 
heart membranes. The allosteric interaction of TMB-8 
was clearly demonstrated in figs 2,3 and 5 by the up- 
ward shift of the dissociation curves [ 1 l-131 with in- 
creasing concentrations of TMB-8, corresponding to a 
decrease in the dissociation rate constants (table 1). 
Thus, TMB-8 stabilized the [3H]NMS-receptor com- 
plex in these membranes. 
The differential effect of TMB-8 only on the 
dissociation kinetics of [3H]NMS from the muscarinic 
receptor subtypes (table l), and not on the inhibition 
constants (Ki G 4 PM in all four membranes), indicated 
that TMB-8 was not a selective agent for the 
antagonist-binding site of the subtypes. Rather, TMB-8 
was selective for allosteric site(s) of the muscarinic 
receptors, and is unlike the receptor selectivity of sub- 
type specific ligands such as pirenzepine or AF-DX 116, 
which are directed towards the Ml and M2 antagonist- 
binding sites, respectively [14- 171. 
The computer generated models of TMB-8 and 
atropine were energy-minimized and then superimpos- 
ed (fig.6). Two important functional groups, the ester 
and the bulky hydrophobic groups, could be overlayed 
in close proximity, while the protonated nitrogen group 
in TMB-8 was more distant from the carbonyl oxygen 
of the ester group than observed for atropine, 7.0 A 
compared to 4.9 A, respectively. An optimum 
geometric distance of 5.1-5.2 A between the pro- 
tonated nitrogen and the carbonyl oxygen has been 
determined for antagonists [22,24]. The increased 
distance could be responsible partially for the 2000-fold 
reduced potency of TMB-8 compared to atropine. Ad- 
ditionally and unlike atropine, TMB-8 has a flexible 
eight-carbon aliphatic chain between the ester and the 
protonated nitrogen, which would permit other low 
energy conformations where the TMB-8 nitrogen does 
not correspond to the location of the atropine nitrogen. 
These alternative TMB-8 conformations might bind to 
an allosteric site in the receptor subtypes of the cortex, 
heart, and ileum. Based on the different dissociation 
kinetics observed for each membrane, the allosteric 
sites were probably not identical in each receptor sub- 
type, and the pancreas receptor subtype lacked an 
allosteric site. The flexibility or rigidity of an an- 
tagonist has been proposed as a mechanism by which a 
compound can attain the conformation necessary to in- 
teract with subtypes of muscarinic receptors [25]. 
Typical doses of TMB-8 used to block internal 
calcium mobilization range from 10 to 200 PM [4]. The 
I&, values for TMB-8 inhibition of the four 
muscarinic receptor subtypes examined in this report 
were approx. 20pM (fig.l), or Ki values of about 
4 yM. These values are well within the dose of TMB-8 
which affects pharmacological responses of the pan- 
creas; the extrapolated ICSO values derived from the 
curves in [6] were about 50 PM for inhibiting cu-amylase 
release or inhibiting the initial rise in internal Ca’+. 
Since TMB-8 can act directly at the receptor, both com- 
petitively and allosterically, it would be expected that 
calcium mobilization induced by muscarinic receptor 
stimulation, or any second messenger system coupled 
to the muscarinic receptors, to be inhibited by TMB-8. 
/ TMB-8 I 
Fig.6. Modeled structures of TMB-8 and atropine, which have been 
energy-minimized and then superimposed. The structures were then 
compared by minimizing the distance between three groups 
important for potency at the muscarinic receptor (see section 4; 
PW41). 
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